Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The inauguration of a new joint Shoklo Malaria Research Unit (SMRU) and Borderland Health Foundation (BHF) Building took place in Mae Ramat, Thailand, this week.

Group photo of the opening of a new building at SMRU © SMRU/Borderland Health Foundation (BHF)

This joint venture was funded by the Wellcome Trust and the Nuffield Department of Medicine and will provide quality health care to the marginalized populations living on both sides of the Thai-Myanmar border in the Mae Sot area, and Tak Province. SMRU delivers this through a unique combination of research and humanitarian services, with an emphasis on maternal-child health and infectious diseases.

The ceremony commenced with speeches by the deputy chief of the Tak Provincial Health Authority; Prof Chris Conlon, Head of NDM's Centre for Tropical Medicine and Global Health; and Dr Julia Kemp from the Wellcome Trust. Dr Supakit Sirilak, Deputy Permanent Secretary of Ministry of Public Health, from the Thai Ministry of Public Health. The building was then formally opened in a ribbon-cutting ceremony by Dr Supakit, Dr Kemp, Prof Gavin Screaton, Head of the Medical Sciences Division, and Prof François Nosten, the founding Director of both SMRU and BHF.

Amongst the delegates were Dr Suta  Pattarakijroongrueng, Director Mae Ra Mart Hospital; Mr Boonliem  Takham, Mae Ra Mart District Administration; Ms Amornrat Tatsanakit, Director Regional Medical Science Center 2 Phitsanulok, Dr Wittaya  Polseela and Dr Purichat Yingrangsan from Tak PHO, as well as representatives from local hospitals, community-based organisations and NGOs and the construction company.

SMRU provides logistical support and has laboratory facilities including a malaria lab, haematology lab, insectary, microbiology lab and freezer room. It provides community engagement, maternal and child health, malaria elimination task force and a tuberculosis programme to the over 130,000 Karen, Mon, Karenni ethnic minority groups living in a string of refugee camps along the Thai-Myanmar border.

Similar stories

Pilot study detects diverse DNA in ingredients of falsified tablets

A recent multidisciplinary pilot study, originating from LOMWRU and the Medicine Quality Research Group of IDDO and MORU, investigated whether bacterial, plant, fungal and animal DNA in the ingredients and from the environment (eDNA) could be detected from falsified (aka counterfeit) tablets.

COPCOV investigators meet, and prepare to submit for publication

On 15-16 Dec, COPCOV investigators from around the world met in Bangkok to review study results and plan next steps. Led by co-PIs Prof Sir Nick White and Dr Will Schilling, and funded by the Wellcome Trust, the MORU-led COPCOV ( Chloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting) is the world’s largest multinational trial of COVID-19 prevention.

Researchers call for antimicrobial resistance surveillance to be improved

The number of studies reporting antimicrobial resistance (AMR) data has increased in Africa, South and South East Asia according to new research in the International Journal of Infectious Diseases.

Are we getting tafenoquine dosing right?

Researchers analysing clinical trial data for the new antimalarial drug tafenoquine find that higher doses are needed to cure reliably vivax malaria infection.

Constant genetic surveillance necessary to keep multidrug-resistant malaria parasite strains in check, study finds

Continually monitoring malaria parasite populations is necessary to prevent outbreaks of previously dormant multidrug-resistant malaria strains, say University of Oxford researchers. Multidrug-resistant malaria parasite strains can rapidly grow or collapse in response to public health policy changes, say the researchers in a study published today in The Lancet.

Meta-analysis informed the updated WHO guidelines for treatment of uncomplicated malaria in the first trimester of pregnancy

A new WWARN meta-analysis, commissioned by the World Health Organization and which informed a change to its treatment guidelines, has been published in The Lancet. The study provides compelling evidence that artemether-lumefantrine should now replace quinine as the treatment of choice in the first trimester.